We are live on ! Find out more
PCM

Peregrine Capital Management Portfolio holdings

AUM $3.08B
1-Year Est. Return 29.51%
This Fund
S&P 500
This Quarter Est. Return
-0.08%
1 Year Est. Return
+29.51%
3 Year Est. Return
+95.04%
5 Year Est. Return
+107.83%
10 Year Est. Return
+715.34%
AUM
$4.82B
AUM Growth
-$754M
Cap. Flow
-$652M
Cap. Flow %
-13.51%
Top 10 Hldgs %
17.2%
Holding
352
New
16
Increased
19
Reduced
233
Closed
17

Sector Composition

Rank Sector Weight
1 Technology 21.44%
2 Healthcare 18.32%
3 Financials 15.21%
4 Consumer Discretionary 12.02%
5 Industrials 11.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PGTI
226
DELISTED
PGT, Inc.
PGTI
$8.07M 0.17%
422,519
-84,094
-17% -$1.8M
OPLN
227
Openlane
OPLN
$4.48B
$7.82M 0.16%
476,836
-42,820
-8% -$722K
CERS icon
228
Cerus
CERS
$516M
$7.78M 0.16%
1,277,815
-252,211
-16% -$1.47M
COOK icon
229
Traeger
COOK
$178M
$7.74M 0.16%
+7,395
New +$9.23M
THRY icon
230
Thryv Holdings
THRY
$95.1M
$7.71M 0.16%
256,744
-53,404
-17% -$1.68M
DY icon
231
Dycom Industries
DY
$12.1B
$7.71M 0.16%
108,234
-21,222
-16% -$1.5M
COMP icon
232
Compass
COMP
$9.74B
$7.49M 0.16%
565,191
-111,604
-16% -$1.6M
PRVA icon
233
Privia Health
PRVA
$2.81B
$7.48M 0.16%
317,596
+11,392
+4% +$398K
MNRO icon
234
Monro
MNRO
$365M
$7.33M 0.15%
127,405
-25,111
-16% -$1.47M
MRTX
235
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.3M 0.15%
41,259
-23,902
-37% -$3.85M
DK icon
236
Delek US
DK
$3.92B
$7.21M 0.15%
401,382
-82,792
-17% -$1.41M
ARNA
237
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.94M 0.14%
116,608
-22,922
-16% -$1.35M
SWX icon
238
Southwest Gas
SWX
$6.63B
$6.9M 0.14%
103,103
-21,245
-17% -$1.48M
EBIX
239
DELISTED
Ebix Inc
EBIX
$6.85M 0.14%
254,530
-52,448
-17% -$1.54M
TPTX
240
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$6.82M 0.14%
102,652
-20,331
-17% -$1.45M
FOLD
241
DELISTED
Amicus Therapeutics
FOLD
$6.78M 0.14%
709,852
-10,734
-1% -$110K
GLDD
242
DELISTED
Great Lakes Dredge & Dock
GLDD
$6.74M 0.14%
446,453
-92,116
-17% -$1.37M
ANDE icon
243
Andersons Inc
ANDE
$2.18B
$6.42M 0.13%
208,258
-42,249
-17% -$1.22M
EBS icon
244
Emergent Biosolutions
EBS
$228M
$6.34M 0.13%
126,613
-24,387
-16% -$1.48M
DV icon
245
DoubleVerify
DV
$2.03B
$6.15M 0.13%
180,145
-35,660
-17% -$1.26M
AOS icon
246
A.O. Smith
AOS
$8.65B
$5.5M 0.11%
90,000
-17,790
-17% -$1.24M
IOVA icon
247
Iovance Biotherapeutics
IOVA
$2.94B
$5.08M 0.11%
205,834
-40,748
-17% -$960K
ZVIA icon
248
Zevia
ZVIA
$105M
$4.95M 0.1%
+429,760
New +$5.7M
WW
249
DELISTED
WW International
WW
$4.79M 0.1%
+262,545
New +$6.86M
IONS icon
250
Ionis Pharmaceuticals
IONS
$9.21B
$4.55M 0.09%
135,787
-26,741
-16% -$1.01M

Similar funds

Peregrine Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Peregrine Capital Management held 352 positions worth $4.82B, down 14% from $5.58B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Peregrine Capital Management withdrew a net $652M in Q3 2021, closing 17 positions and reducing 233 holdings. Its most notable exit was PRA Health Sciences, Inc., an estimated $19.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Peregrine Capital Management opened a new position in Penguin Solutions Inc worth $14.6M.

  • Peregrine Capital Management's largest Q3 2021 buy was Penguin Solutions Inc: 654,160 shares worth $14.6M.
  • Peregrine Capital Management added most to Teladoc Health in Q3 2021, an estimated $8.07M increase.
  • Peregrine Capital Management's biggest Q3 2021 reduction was Generac Holdings, cutting an estimated $22.3M.
  • Peregrine Capital Management fully exited PRA Health Sciences, Inc. in Q3 2021, selling an estimated $19.2M.
  • Peregrine Capital Management's ten largest holdings make up 17% of its $4.82B portfolio in Q3 2021.
  • Peregrine Capital Management opened 16 new positions and closed 17 in Q3 2021.
  • Peregrine Capital Management's portfolio value fell 14% quarter-over-quarter to $4.82B.

Based on Peregrine Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.